OLD Republic International Corp Has $55.23 Million Holdings in Johnson & Johnson (NYSE:JNJ)

OLD Republic International Corp raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 333,000 shares of the company's stock after buying an additional 4,000 shares during the period. Johnson & Johnson comprises 2.1% of OLD Republic International Corp's portfolio, making the stock its 21st biggest position. OLD Republic International Corp's holdings in Johnson & Johnson were worth $55,225,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Lantz Financial LLC grew its stake in shares of Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after purchasing an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $453,000. Joel Isaacson & Co. LLC boosted its stake in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after acquiring an additional 2,526 shares during the last quarter. State of Wyoming boosted its stake in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after acquiring an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC boosted its stake in Johnson & Johnson by 18.9% in the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after acquiring an additional 2,529 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $0.82 on Friday, reaching $156.87. 7,866,488 shares of the stock were exchanged, compared to its average volume of 8,066,975. The firm's 50 day moving average is $153.75 and its 200-day moving average is $154.43. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a market cap of $377.44 billion, a PE ratio of 17.45, a P/E/G ratio of 2.15 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several analyst reports. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Bank of America lowered their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.